1. Search Result
Search Result
Results for "

NCI–H929

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

1

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-172085

    IFNAR DNA/RNA Synthesis c-Myc CDK Cancer
    SH514 is an orally active IRF4 inhibitor (IC50 = 2.63 μM). SH514 binds to the IRF4-DBD domain, thereby inhibiting the interaction of IRF4 protein with DNA (KD = 1.28 μM). SH514 can inhibit the proliferation of IRF4-high-expressing NCI-H929 and MM.1R cells, and displays no cytotoxicity for normal cells. SH514 significantly downregulates the expression of IRF4 downstream target genes concentration-dependently. SH514 inhibits the expression of cell cycle-related proteins CDC2, Cyclin B1, Cyclin D1, Cyclin E1, and CMYC in Multiple Myeloma cells. SH514 can induce DNA damage and increase the expression of γH2AX. SH514 effectively inhibits the proliferation of multiple myeloma tumors .
    SH514
  • HY-144841A

    (Rac)-CFT7455

    Molecular Glues Cancer
    (Rac)-Cemsidomide ((Rac)-CFT7455) is the racemate of Cemsidomide (HY-144841) with antitumor activity . Cemsidomide is a ubiquitin ligase pathway Ikaros/Aiolos degrader with molecular glue activity. Cemsidomide has a GI50 of 0.05 nM for NCIH929.1 cells.
    (Rac)-Cemsidomide
  • HY-144841

    CFT7455

    Molecular Glues IKZF Family Cancer
    Cemsidomide (CFT7455) is a ubiquitin ligase pathway based IKZF1/3 (Ikaros/Aiolos) degrader with molecular glue activity . Cemsidomide has a GI50 of 0.05 nM for NCIH929.1 cells. Cemsidomide is used in the research of multiple myeloma (MM) .
    Cemsidomide
  • HY-P991462

    CD38 Cancer
    GBR-1342 is a human bispecific antibody (bsAb) targeting CD38 & CD3. GBR-1342 inhibits the activity of Daudi, RAJI, RPMI8226, IM-9, and NCI-H929 cancer cell lines. GBR-1342 can be used in myeloma research .
    GBR-1342
  • HY-171754

    Antibody-Drug Conjugates (ADCs) Cancer
    LM-305 is an anti-G protein-coupled receptor class 5 member D (GPRC5D) antibody-drug conjugate (ADC). LM-305 consists of Anti-GPRC5D Antibody (HY-P991197) and VcMMAE (HY-15575). LM-305 exhibits potent cytotoxicity against multiple myeloma cells (NCI-H929 and MM.1R) with IC50 values ranging from 0.1 to 0.3 nM. LM-305 can be used in the study of GPRC5D-related relapsed and refractory multiple myeloma (RRMM) .
    LM-305
  • HY-175502

    Molecular Glues IKZF Family Apoptosis Cancer
    MGD-22, a molecular glue, is an orally active IKZF1/2/3 degrader with DC50 values of 8.33 nM, 9.91 nM, and 5.74 nM, respectively. MGD-22 exhibits extremely potent anti-proliferative activity against diverse hematological cancer cells. MGD-22 induces apoptosis in cancer cells. MGD-22 demonstrates potent anti-tumor efficacy in mice bearing NCI-H929 xenografts or WSU-DLCL-2 xenografts. MGD-22 can be used for the study of hematological cancers, including multiple myeloma (MM), acute myeloid leukemia (AML), and diffuse large B-cell lymphoma (DLBCL) .
    MGD-22
  • HY-149513

    c-Myc Apoptosis Cancer
    EP12 is a c-Myc inhibitor. EP12 is a c-Myc G4 stabilizer. EP12 induces apoptosis and DNA damage in multiple myeloma cells. EP12 disrupts the nuclear translocation of P65/P50 by interfering with the NF-κB signaling pathway. EP12 inhibits multiple myeloma growth .
    EP12

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: